{
    "clinical_study": {
        "@rank": "84013", 
        "arm_group": {
            "arm_group_label": "Cabazitaxel", 
            "arm_group_type": "Experimental", 
            "description": "Cabazitaxel 20 mg/m2 over 1 hour i.v., repeated on day 22"
        }, 
        "brief_summary": {
            "textblock": "Single-arm study to determine response rate in second-line treatment with cabazitaxel after\n      the failure of palliative primary treatment."
        }, 
        "brief_title": "Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer", 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "65 patients with advanced or metastatic adenocarcinoma of the oesophagogastric junction and\n      stomach will be treated with 20mg/m2 Cabazitaxel for a maximum of 6 cycles. Main objective\n      of the study is the response rate with Cabazitaxel."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed inoperable and/or metastatic adenocarcinoma of the\n             oesophagogastric junction or stomach\n\n          2. Progression of a measurable lesion (RECIST) on previous palliative chemotherapy.\n             Neoadjuvant/adjuvant treatment is not counted, unless progression occurs < 6 months\n             after completion of the treatment. In these cases, neoadjuvant/adjuvant treatment is\n             counted as one line.\n\n          3. Male and female patients aged > 18 years\n\n          4. ECOG \u2264 1\n\n          5. neutrophils \u2265 1500/\u00b5l\n\n          6. Haemoglobin \u2265 9 g/dl\n\n          7. Platelets \u2265 100,000/\u00b5l\n\n          8. AST/SGOT and/or ALT/SGPT \u22642.5 x ULN;\n\n          9. Total bilirubin \u22641.0 x ULN\n\n         10. Serum creatinine \u2264 1.5 times the normal value, or creatinine clearance \u2265 60 ml/min\n\n         11. Written patient informed consent\n\n        Exclusion Criteria:\n\n          1. A history of severe hypersensitivity to taxanes (\u2265 grade 3) or to medicinal products\n             containing polysorbate 80 (\u2265 grade 3)\n\n          2. Active CAD, cardiomyopathy or NYHA stage III-IV heart failure\n\n          3. Malignant secondary disease dating back < 5 years (exceptions: in situ cervical\n             carcinoma, appropriately treated basal cell carcinoma of the skin)\n\n          4. Severe secondary internal diseases, including uncontrolled diabetes mellitus or an\n             acute infection\n\n          5. Concomitant medication or planned treatment with strong CYP450 3A4/5 inducers or\n             inhibitors (list of medicinal products in the appendix) or the relevant medicinal\n             products were not discontinued a minimum of one week before treatment\n\n          6. Peripheral polyneuropathy > NCI grade II\n\n          7. Severe hepatic impairment (AST/ALT > 2.5 x ULN, , bilirubin > 1 x ULN)\n\n          8. Chronic inflammatory bowel disease\n\n          9. Participation in another study\n\n         10. Pregnancy or lactation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01956149", 
            "org_study_id": "CabaGast"
        }, 
        "intervention": {
            "arm_group_label": "Cabazitaxel", 
            "description": "20 mg/m2 over 1 hour i.v., repeated on day 22 for maximum 6 cycles.", 
            "intervention_name": "Cabazitaxel", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "gastric cancer", 
            "second-line treatment", 
            "Cabazitaxel", 
            "response"
        ], 
        "lastchanged_date": "January 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "albatran@aol.com", 
                    "last_name": "Salah-Eddin Al-Batran, MD", 
                    "phone": "+496976014420"
                }, 
                "contact_backup": {
                    "email": "pauligk.claudia@khnw.de", 
                    "last_name": "Claudia Pauligk, PhD", 
                    "phone": "+496976013906"
                }, 
                "facility": {
                    "address": {
                        "city": "Frankfurt am Main", 
                        "country": "Germany", 
                        "zip": "60488"
                    }, 
                    "name": "Krankenhaus Nordwest"
                }, 
                "investigator": {
                    "last_name": "Salah-Eddin Al-Batran, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Harald.Schmalenberg@med.uni-jena.de", 
                    "last_name": "Harald Schmalenberg, MD", 
                    "phone": "+493641933114"
                }, 
                "facility": {
                    "address": {
                        "city": "Jena", 
                        "country": "Germany", 
                        "zip": "07747"
                    }, 
                    "name": "Universit\u00e4tsklinikum Jena"
                }, 
                "investigator": {
                    "last_name": "Harald Schmalenberg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Multicentre, Phase II Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Adenocarcinoma of the Oesophagogastric Junction and Stomach", 
        "overall_contact": {
            "email": "albatran.salah@khnw.de", 
            "last_name": "Salah-Eddin Al-Batran, MD", 
            "phone": "+496976014420"
        }, 
        "overall_contact_backup": {
            "email": "pauligk.claudia@khnw.de", 
            "last_name": "Claudia Pauligk, PhD", 
            "phone": "+496976013906"
        }, 
        "overall_official": {
            "affiliation": "University of Jena", 
            "last_name": "Harald Schmalenberg, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients are staged every 6 weeks during therapy (after cycle 2, 4 and 6, i.e. up to 18 weeks) and during follow-up (up to 12 months)", 
            "measure": "Response Rate", 
            "safety_issue": "No", 
            "time_frame": "up to 17 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01956149"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Krankenhaus Nordwest", 
            "investigator_full_name": "PD Dr. S.E. Al-Batran", 
            "investigator_title": "Principal investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "From date of randomization until the date of death from any cause, assessed up to 17 months", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "up to 17 months"
            }, 
            {
                "description": "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 17 months", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "up to 17 months"
            }, 
            {
                "description": "Patients are staged every 6 weeks during therapy (after cycle 2, 4 and 6, i.e. up to 18 weeks) and during follow-up (up to 12 months)", 
                "measure": "Response rate by subgroup (with and without previous treatment with a taxane)", 
                "safety_issue": "No", 
                "time_frame": "up to 17 months"
            }, 
            {
                "description": "incidence and intensity of adverse events", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "up to 18 weeks"
            }, 
            {
                "description": "samples for analysis of circulating tumor cells are taken before therapy, before every new cycle, and at the end of treatment (every 3 weeks).", 
                "measure": "Correlation of circulating tumor cells with PFS and OS", 
                "safety_issue": "No", 
                "time_frame": "up to 18 weeks"
            }, 
            {
                "measure": "Correlation of circulating tumor cells with the clinical response", 
                "safety_issue": "No", 
                "time_frame": "up to 18 weeks"
            }
        ], 
        "source": "Krankenhaus Nordwest", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Krankenhaus Nordwest", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}